Articles

Analysis of patients in ZUMA-7 who necessitated further therapy revealed that re-treatment with CAR-T therapy may be viable after an initial response in the 2L setting. Read More ›

Real-world analysis of outcomes with axi-cel in patients with LBCL by race and ethnicity revealed favorable response rates, with lower response rates observed in African-American patients. Read More ›

Real-world study of patients with R/R LBCL found axi-cel to provide clinically meaningful benefits to patients of all ages versus chemoimmunotherapy, with larger relative benefits in those age ≥65 years. Read More ›

Retrospective analysis found disparities in access to CAR-T therapy in the US, particularly in female patients and patients residing in southern states. Read More ›

The primary analysis of the PILOT study revealed durable overall and complete response rates in patients with LBCL not intended for stem-cell transplantation treated with liso-cel in the 2L setting. Read More ›

Meta-analysis of CAR-T therapy versus high-dose chemotherapy followed by ASCT in 2L R/R LBCL demonstrated superior outcomes with CAR-T without excess toxicity. Read More ›

Retrospective observational study of treatment patterns and real-world outcomes for 2L treatment of patients with relapsed or refractory LBCL demonstrated poor prognosis in those unable to derive benefit from conditioning followed by stem-cell transplantation. Read More ›

Through testing and validation, the novel CAR-T‒specific comorbidity index demonstrated that comorbidities are predictive of mortality after CAR-T therapy. Read More ›

A novel RADscore based on correlation of radiomic features with clinical outcomes in patients with R/R LBCL receiving CAR-T therapy outperformed conventional PET parameters for prognostication. Read More ›